Citations

Showing 10 of 108119 citations.

GATA‐3 and T‐bet as diagnostic markers of non‐esophageal eosinophilic gastrointestinal disease
Neely, Joseph, Reimers, Annika, Garg, Shipra , Masuda, Mia Y. , Schroeder, Shauna , Wright, Benjamin L. , Doyle, Alfred D. , Wright, Benjamin L , Taylor, Steve

Mayo Clinic

Allergy | November 4, 2021 | Volume: 77 | Issue: 3 | Pages: 1042-1044

10.1111/all.15171 | PMID 34735725 Get It

In-hospital Clinical Complications of COVID-19: A Brief Overview
John, Kevin , Nayar, Jemimah , Selvaraj, Vijairam , Lal, Amos , John, Kevin John , Lal, Amos , Mishra, Ajay Kumar , Khan, Mohammad Saud

Mayo Clinic

Future Virology | November 4, 2021 | Volume: 16 | Issue: 11 | Pages: 717-723

10.2217/fvl-2021-0200 | PMID 34777553 Get It

Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and Growth
Cook, Danielle , Martin, Timothy D. , Galanko, Joseph A. , Loeza, Gabriela Herrera, Trembath, Dimitri G. , Justilien, Verline , Pickering, Karen , Jarosch, Armin , Jurmeister, Philipp , Waters, Andrew M. , Hibshman, Priya S. , Campbell, Andrew D. , Yeh, Jen Jen , Lee, Michael S. , Fields, Alan P. , Sandler, Robert S. , Sansom, Owen J. , Sers, Christine , Schaefer, Antje , Martin, Timothy D , Trembath, Dimitri G , Justilien, Verline , Pickering, Karen A , Waters, Andrew M , Lee, Michael S , Cox, Adrienne D , Sandler, Robert S , Sansom, Owen J , Sers, Christine , Schaefer, Antje , Kang, Melissa S , Loeza, Gabriela H., Vincent, David F. , Ford, Catriona A. , Keku, Temitope O , Cox, Adrienne D. , Der, Channing J

Mayo Clinic

Cancer Research | November 4, 2021 | Volume: 82 | Issue: 1 | Pages: 90-104

10.1158/0008-5472.can-20-4218 | PMID 34737214 Get It

Abstract ECT2 is an activator of RHO GTPases that is essential for cytokinesis. In addition, ECT2 was identified as an oncoprotein when expressed ectopically in NIH/3T3 fibroblasts. However, oncogenic activation of ECT2 resulted from N-terminal truncation, and such truncated ECT2 proteins have not been found in patients with cancer. In this study, we observed elevated expression of full-length ECT2 protein in preneoplastic colon adenomas, driven by increased ECT2 mRNA abundance and associated with APC tumor-suppressor loss. Elevated ECT2 levels were detected in the cytoplasm and nucleus of colorectal cancer tissue, suggesting cytoplasmic mislocalization as one mechanism of early oncogenic ECT2 activation. Importantly, elevated nuclear ECT2 correlated with poorly differentiated tumors, and a low cytoplasmic:nuclear ratio of ECT2 protein correlated with poor patient survival, suggesting that nuclear and cytoplasmic ECT2 play distinct roles in colorectal cancer. Depletion of ECT2 reduced anchorage-independent cancer cell growth and invasion independent of its function in cytokinesis, and loss of Ect2 extended survival in a KrasG12D Apc-null colon cancer mouse model. Expression of ECT2 variants with impaired nuclear localization or guanine nucleotide exchange catalytic activity failed to restore cancer cell growth or invasion, indicating that active, nuclear ECT2 is required to support tumor progression. Nuclear ECT2 promoted ribosomal DNA transcription and ribosome biogenesis in colorectal cancer. These results support a driver role for both cytoplasmic and nuclear ECT2 overexpression in colorectal cancer and emphasize the critical role of precise subcellular localization in dictating ECT2 function in neoplastic cells. Significance: ECT2 overexpression and mislocalization support its role as a driver in colon cancer that is independent from its function in normal cell cytokinesis.
Management recommendations for pancreatic manifestations of von Hippel–Lindau disease
Leeuwaarde, Rachel van, Keutgen, Xavier M. , Nilubol, Naris , Links, Thera P. , Daniels, Anthony B. , Tirosh, Amit , Laks, Shachar , Patel, Dhaval , Hammel, Pascal , Hálfdánarson, Þorvarður R.

Mayo Clinic

Cancer | November 4, 2021 | Volume: 128 | Issue: 3 | Pages: 435-446

10.1002/cncr.33978 | PMID 34735022 Get It

Von Hippel–Lindau disease (VHL) is a multineoplasm inherited disease manifesting with hemangioblastoma of the central nervous system and retina, adrenal pheochromocytoma, renal cell carcinoma, pancreatic neuroendocrine tumors and cysts, and neoplasms/cysts of the ear, broad ligament, and testicles. During 2018‐2020, the VHL Alliance gathered several committees of experts in the various clinical manifestations of VHL to review the literature, gather the available evidence on VHL, and develop recommendations for patient management. The current report details the results of the discussion of a group of experts in the pancreatic manifestations of VHL along with their proposed recommendations for the clinical surveillance and management of patients with VHL. The recommendations subcommittee performed a comprehensive systematic review of the literature and conducted panel discussions to reach the current recommendations. The level of evidence was defined according to the Shekelle variation of the Grading of Recommendations, Assessment, Development, and Evaluation grading system. The National Comprehensive Cancer Network Categories of Evidence and Consensus defined the committee members' interpretation of the evidence and degree of consensus. The recommendations encompass the main aspects of VHL‐related pancreatic manifestations and their clinical management. They are presented in a clinical orientation, including general planning of screening and surveillance for pancreatic neuroendocrine tumors, utility of biochemical biomarkers, the optimal choice for imaging modality, indirect risk stratification, indications for tissue sampling of VHL‐related pancreatic neuroendocrine tumors, and interventions. These recommendations are designed to serve as the reference for all aspects of the screening, surveillance, and management of VHL‐related pancreatic manifestations.
IQ in Autism Spectrum Disorder: A Population-Based Birth Cohort Study
Katušić, Maja , Myers, Scott M. , Weaver, Amy L. , Voigt, Robert G. , Katusic, Maja Z, Katusic, Maja Z.

Mayo Clinic

Pediatrics | November 4, 2021 | Volume: 148 | Issue: 6 | Pages: No page available

10.1542/peds.2020-049899 | PMID 34851412 Get It

OBJECTIVES We aimed to describe the intellectual ability and ratio of boys to girls with average or higher IQ within autism spectrum disorder (ASD) cases identified in a population-based birth cohort. We hypothesized that research-identified individuals with ASD would be more likely to have average or higher IQ, compared to clinically diagnosed ASD. We also hypothesized the male to female ratio would decrease as the definition of ASD broadened. METHODS ASD incident cases were identified from 31 220 subjects in a population-based birth cohort. Research-defined autism spectrum disorder, inclusive criteria (ASD-RI) was based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, autistic disorder (AD), Asperger Disorder, and pervasive developmental disorder not otherwise specified criteria. Research-defined autism spectrum disorder, narrow criteria (ASD-RN) was a narrower definition based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision AD criteria. Clinical diagnoses of ASD were abstracted from medical and school records. Intellectual ability was based on the last IQ score or on documented diagnoses of intellectual disability if no scores available. Average or higher IQ was defined as IQ ≥86. RESULTS A total of 59.1% of those with ASD-RI (n = 890), 51.2% of those with ASD-RN (n = 453), and 42.8% of those with clinically diagnosed autism spectrum disorder (n = 187) had average or higher IQ. Within the ASD-RI and ASD-RN groups, boys were more likely than girls to have an average or higher IQ (62.0% vs 51.3% [P = .004] and 54.1% vs. 42.5% [P = .03], respectively). CONCLUSION Our data suggest that nearly half of individuals with ASD have average or higher IQ. Boys with ASD are more likely to have average or higher IQ than girls. Patients with ASD and higher IQ remain at risk for not being identified.
Open Cholecystostomy Under Local Anesthesia for Acute Cholecystitis in the Elderly and High-Risk Surgical Patients
Slama, Eliza , Hosseini, Motahar , Staszak, Ryan M. , Setya, Viney

Mayo Clinic

The American Surgeon™ | November 4, 2021 | Volume: 88 | Issue: 3 | Pages: 434-438

10.1177/00031348211050593 | PMID 34734555 Get It

Background The morbidity and mortality rates associated with cholecystectomy for acute cholecystitis are higher in the critically ill elderly population. As an alternative to cholecystectomy, we report the results of treatment of acute cholecystitis in the elderly after open cholecystolithotomy with cholecystostomy tube placement under local anesthesia. Methods A case series was performed on 5 patients from August 2007 to April 2010 who presented with acute cholecystitis and underwent an open cholecystolithotomy and tube placement. Thirty-day mortality, intra- and immediate-postoperative complications, clinical improvement after drainage, additional biliary procedures needed, and outcome after cholecystostomy tube removal were recorded. Results Open cholecystolithotomy and tube placement were performed successfully in all patients and permitted resolution of the acute attack in all after a mean period of 3.75 days. Thirty-day mortality was 0%. Patients did not experience any intraoperative complications. We observed 100% rate of successful short-term outcomes in our patients including resolution pain, and objectively, normalization of leukocytosis, and defervescence. None of the patients required emergency cholecystectomy. All patients had their cholecystostomy tubes removed at a mean postoperative day 27. There were no cases of biliary leakage or tube dislodgement. There were no recurrences of acute cholecystitis within the mean follow-up of 20.75 months. Discussion Emergency open cholecystolithotomy and cholecystostomy tube placement represent an effective, safe, and definitive alternative treatment strategy for acute gallstone cholecystitis in selected elderly patients with a mortality rate of 0% in the authors’ experience.
512 The rising incidence, prevalence and mortality gap of lupus nephritis: a population-based study over four decades
Valenzuela-Almada, Maria O , Dabit, Jesse Y. , Osei‐Onomah, Shirley‐Ann, Crowson, Cynthia S. , Hocaoǧlu, Mehmet , Chevet, Baptiste , Giblon, Rachel , Duarte‐García, Alí

Mayo Clinic

Abstracts | November 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: A19.1-A19

10.1136/lupus-2021-lupus21century.30 Get It

Orthopaedic Group Practice Size Is Increasing
Haglin, Jack M. , Brinkman, Joseph C. , Chhabra, Anikar , Doan, Matthew K. , Chhabra, Anikar , Pollock, Jordan Riley , Moore, M. Lane , Hogan, Jacob S.

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | November 4, 2021 | Volume: 3 | Issue: 6 | Pages: No page available

10.1016/j.asmr.2021.09.015 | PMID 34977651 Get It

Purpose To analyze recent trends in orthopaedic surgery consolidation and quantify these changes temporally and geographically from 2012 to 2020. Methods We performed a retrospective cross‐sectional analysis of orthopaedic surgeon practice size in the United States using 2012 and 2020 data obtained from the Physician Compare database. Results Although we observed an increase from 21,216 unique orthopaedic surgeons in 2012 to 21,553 in 2020 (1.6% increase), the number of practices experienced a large decrease from 7,299 practices in 2012 to 5,829 in 2020 (20.1% decrease). The proportion of orthopaedic surgeons working in solo practices decreased from 13.2% (2,790) in 2012 to 7.4% (1,595) in 2020, and the proportion of orthopaedic surgeons working in groups sized 2 to 24 decreased from 35.3% (7,482) in 2012 to 22.2% (4,775) in 2020. In contrast, groups sized 25 to 99 have grown from 20.7% (4,387) of all orthopaedic surgeons to 23.4% (5,048) in 2020. Groups sized 100 to 499 have increased from 16.9% (3,593) in 2012 to 24.1% (5,190) in 2020, whereas groups sized 500 or greater have grown from 14% (2,964) in 2012 to 22.9% (4,945) in 2020. The number of unique group practices showed a significant decrease in the number of solo groups, which comprised 43.8% (3,200) of the total number of individual practices in 2012, decreasing to 32% (1,886) in 2020. All other groups increased in number and proportionally from 2012 to 2020. Conclusions This study shows that over the period from 2012 to 2020, there has been a substantial trend of orthopaedic surgeons shifting to increasing practice sizes, potentially indicating that more orthopaedic surgeons are working for large health care organizations rather than small independent practices. Clinical Relevance The impact of these changes should be examined to determine large‐scale effects on patient care, payment models, access, and outcomes, along with physician compensation, lifestyle, and satisfaction.
Combined Drainage and Protocolized Necrosectomy Through a Coaxial Lumen-apposing Metal Stent for Pancreatic Walled-off Necrosis
Dayyeh, Barham K. Abu, Chandrasekhara, Vinay, Shah, Raj J., Easler, Jeffrey J., Storm, Andrew C., Topazian, Mark, Levy, Michael J., Martin, John A., Petersen, Bret T., Takahashi, Naoki, Edmundowicz, Steven, Hammad, Hazem, Wagh, Mihir S., Wani, Sachin, DeWitt, John, Bick, Benjamin, Gromski, Mark, Haddad, Mohammad Al, Sherman, Stuart, Merchant, Ambreen A., Peetermans, Joyce A., Gjata, Ornela, McMullen, Edmund, Willingham, Field F., Takahashi, Naoki , Takahashi, Naoki , Dayyeh, Barham K. Abu, Chandrasekhara, Vinay, Shah, Raj J., Easler, Jeffrey J., Storm, Andrew C., Topazian, Mark, Levy, Michael J., Martin, John A., Petersen, Bret T., Takahashi, Naoki, Edmundowicz, Steven, Hammad, Hazem, Wagh, Mihir S., Wani, Sachin, DeWitt, John, Bick, Benjamin, Gromski, Mark, Haddad, Mohammad Al, Sherman, Stuart, Merchant, Ambreen A., Peetermans, Joyce A., Gjata, Ornela, McMullen, Edmund, Willingham, Field F.

Mayo Clinic

Annals of Surgery | November 4, 2021 | Volume: 277 | Issue: 5 | Pages: e1072-e1080

10.1097/sla.0000000000005274 | PMID 35129503 Get It

Objective: We evaluated a protocolized endoscopic necrosectomy approach with a lumen-apposing metal stent (LAMS) in patients with large symptomatic walled-off pancreatic necrosis (WON) comprising significant necrotic content, with or without infection. Summary Background Data: Randomized trials have shown similar efficacy of endoscopic treatment compared with surgery for infected WON. Design: We conducted a regulatory, prospective, multicenter single-arm clinical trial examining the efficacy and safety of endoscopic ultrasound -guided LAMS with protocolized necrosectomy to treat symptomatic WON ≥6 cm in diameter with >30% solid necrosis. After LAMS placement, protocolized WON assessment was conducted and endoscopic necrosectomy was performed for insufficient WON size reduction and persistent symptoms. Patients with radiographic WON resolution to ≤ 3 cm and/or 60-day LAMS indwell had LAMS removal, then 6-month follow-up. Primary endpoints were probability of radiographic resolution by 60 days and procedure-related serious adverse events. Results: Forty consecutive patients were enrolled September 2018 to March 2020, of whom 27 (67.5%) were inpatients and 19 (47.5%) had clinical evidence of infection at their index procedure. Mean WON size was 15.0 ± 5.6 cm with mean 53.2% ± 16.7% solid necrosis. Radiographic WON resolution was seen in 97.5% (95% CI, 86.8%, 99.9%) by 60 days, without recurrence in 34 patients with 6-month follow-up data. Mean time to radiographic WON resolution was 34.1 ± 16.8 days. Serious adverse events occurred in 3 patients (7.5%), including sepsis, vancomycin-resistant enterococcal bacteremia and shock, and upper gastrointestinal bleeding. There were no procedure-related deaths. Conclusions: Endoscopic ultrasound-guided drainage with protocolized endoscopic necrosectomy to treat large symptomatic or infected walled-off necrotic pancreatic collections was highly effective and safe. Clinicaltrials.-gov no: NCT03525808.
Multiple Systemic Vascular Risk Factors Are Associated With Low-Tension Glaucoma
Funk, Robert O., Hodge, David O. , Kohli, Darrell, Roddy, Gavin W.

Mayo Clinic

Journal of Glaucoma | November 3, 2021 | Volume: 31 | Issue: 1 | Pages: 15-22

10.1097/ijg.0000000000001964 | PMID 34731871 Get It

Précis: Multiple systemic vascular-associated conditions including systemic hypertension and hypotension, diabetes mellitus, migraine headache, peripheral vascular disease, Raynaud syndrome, and anemia were associated with low-tension glaucoma. Purpose: The purpose of this study was to identify systemic risk factors associated with low-tension glaucoma. Patients and Methods: A retrospective case-control study design was employed to identify patients seen at the Mayo Clinic Department of Ophthalmology between 2005 and 2015 with low-tension glaucoma and an age-matched and sex-matched control group, each containing 277 patients. Results: The low-tension glaucoma group had more myopic refractive errors (−1.6 vs. −1.0 D, P <0.001), lower intraocular pressure (14.2 vs. 15.2 mm Hg, P <0.001), and a higher cup-to-disc ratio (0.7 vs. 0.3, P <0.001). The low-tension glaucoma group was significantly less likely to be obese (body mass index >30, P =0.03). This group had a significantly higher prevalence of systemic hypertension [odds ratio (OR): 1.64, P =0.004], diabetes mellitus (OR: 3.01, P <0.001), peripheral vascular disease (OR: 2.61, P =0.009), migraine headache (OR: 2.12, P =0.02), anemia (OR: 2.18, P =0.003), systemic hypotension (OR: 4.43, P <0.001), Raynaud syndrome (OR: 3.09, P =0.05), and angiotensin-converting enzyme inhibitor (OR: 1.64, P =0.01) or calcium channel blocker use (OR: 1.98, P =0.004). After adjusting for systemic hypertension, calcium channel blocker use remained significant (OR: 1.70, P =0.03). No significant difference was found between groups with respect to hyperlipidemia, obstructive sleep apnea, coronary artery disease, carotid stenosis, stroke, or statin, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, beta-blocker, or metformin use. Conclusions: Multiple vascular-associated conditions were associated with low-tension glaucoma including systemic hypertension, diabetes mellitus, peripheral vascular disease, migraine headache, Raynaud syndrome, anemia, systemic hypotension, and calcium channel blocker use. This study strengthens the evidence for the vascular hypothesis of low-tension glaucoma.